IRLAB Therapeutics Logo

IRLAB Therapeutics

Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.

IRLAB | ST

Overview

Corporate Details

ISIN(s):
SE0012675361 (+1 more)
LEI:
549300JAT34LHEI0DH60
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IRLAB Therapeutics is a drug discovery and development company specializing in novel treatments for neurodegenerative conditions, with a primary focus on Parkinson's disease and other Central Nervous System (CNS) disorders. The company's pipeline is generated by its proprietary research platform, the Integrative Screening Process (ISP), a systems pharmacology discovery method built on an extensive, unique database of CNS compounds. Key clinical-phase candidates include mesdopetam (IRL790), developed to treat levodopa-induced dyskinesia (LIDs), and pirepemat (IRL752), aimed at addressing impaired balance and falls associated with Parkinson's disease.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-20 16:40
Regulatory News Service
Valberedningen utsedd inför IRLAB:s årsstämma 2026
Swedish 41.3 KB
2025-11-20 16:40
Regulatory News Service
Nomination committee appointed for IRLAB’s annual general meeting 2026
English 40.5 KB
2025-10-29 07:00
Quarterly Report
Swedish 577.5 KB
2025-10-29 07:00
Quarterly Report
English 571.8 KB
2025-10-09 17:15
Board/Management Information
IRLAB utser Gustaf Albèrt till ny Chief Financial Officer
Swedish 39.5 KB
2025-10-09 17:15
Board/Management Information
IRLAB appoints Gustaf Albèrt as the new Chief Financial Officer.
English 39.5 KB
2025-08-29 07:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i IRLAB Therapeutics AB
Swedish 47.7 KB
2025-08-29 07:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in IRLAB Therapeutics AB
English 47.0 KB
2025-08-27 07:00
Interim Report
Swedish 377.6 KB
2025-08-27 07:00
Interim Report
English 373.0 KB
2025-08-21 11:00
Board/Management Information
IRLAB appoints Roy Jonebrant as interim CFO
English 38.2 KB
2025-08-21 11:00
Board/Management Information
IRLAB utser Roy Jonebrant till tillförordnad CFO
Swedish 38.8 KB
2025-08-11 09:00
Board/Management Information
IRLAB's CFO Viktor Siewertz leaves the company for a new leading position
English 39.6 KB
2025-08-11 09:00
Board/Management Information
IRLAB:s CFO Viktor Siewertz lämnar bolaget för ny ledande position
Swedish 40.0 KB
2025-07-18 18:31
Share Issue/Capital Change
IRLAB announces the outcome of the company’s rights issue
English 64.4 KB

Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IRLAB Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-05 Kristina Torfgård Other Buy 9,000 140,850.00 SEK
2024-08-05 Kristina Torfgård Other Buy 4,500 70,875.00 SEK
2024-05-14 Gunnar Olof Olsson Other Buy 2,000 31,000.00 SEK
2024-05-10 Daniel Johnsson Other Buy 20,000 259,680.00 SEK
2023-04-03 Joakim Tedroff Other Buy 51,430 2,038,685.20 SEK
2022-09-01 Richard Godfrey Other Buy 5,000 174,457.00 SEK
2022-08-30 Viktor Siewertz Other Buy 40 1,420.00 SEK
2022-08-29 Viktor Siewertz Other Sell 40 1,408.00 SEK
2022-07-15 Joakim Tedroff Other Other 84,148 N/A
2022-05-31 Viktor Siewertz Other Buy 4,500 170,370.00 SEK

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.